ELB-139

Source: Wikipedia, the free encyclopedia.
ELB-139
Identifiers
  • 1-(4-Chlorophenyl)-4-piperidin-1-yl-1,5-dihydro-imidazol-2-one
JSmol)
  • Clc3ccc(cc3)N1CC(=NC1=O)N2CCCCC2
  • InChI=1S/C14H16ClN3O/c15-11-4-6-12(7-5-11)18-10-13(16-14(18)19)17-8-2-1-3-9-17/h4-7H,1-3,8-10H2
  • Key:YGXIELIREXEJQN-UHFFFAOYSA-N
  (verify)

ELB-139 (LS-191,811) is an anxiolytic drug with a novel chemical structure, which is used in scientific research. It has similar effects to benzodiazepine drugs, but is structurally distinct and so is classed as a nonbenzodiazepine anxiolytic.[1][2]

ELB-139 is a subtype-selective

GABAA receptors, with highest affinity for the α3 subtype, but highest efficacy at α1 and α2.[3] It has primarily anxiolytic and anticonvulsant effects, but produces little sedative effects or ataxia,[4] and has also been demonstrated in rats to increase serotonin levels in the striatum and prefrontal cortex, without affecting dopamine levels.[5] It has been proposed as a possible candidate for a novel non-sedating anxiolytic or anticonvulsant drug for use in humans[6] The sponsor elbion AG registered a clinical trial in ClinicalTrials.gov
for the treatment of anxiety associated with panic disorder but the results have not been reported.[7] It was developed by Arzneimittelwerk Dresden in the 1990s.[8]

References

  1. S2CID 21967108
    .
  2. S2CID 22793644
    .
  3. S2CID 21598180
    .
  4. PMID 16539371
    .
  5. S2CID 22862432
    .
  6. PMID 16621450
    .
  7. PMID 16359919
    .
  8. ^ US 5869481, "Anticonvulsive 1-ar(alk)ylimidazolin-2-ones and process for making" 
Stub icon

This article about an anxiolytic is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=ELB-139&oldid=1134692548"